OP
DNLI icon

ORG Partners’s Denali Therapeutics DNLI Stock Holding History

ORG Partners’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$2.15K Buy
+130
New +$2.19K ﹤0.01% 1434

Other funds holding DNLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ORG Partners's DNLI Position: Q4 2025 in Review

ORG Partners opened a new position in Denali Therapeutics (DNLI) in Q4 2025: 130 shares worth $2.15K. The stake represents ﹤0.01% of the portfolio and ranks #1434 among its holdings.

250 funds tracked by Wall St. Rank hold DNLI as of Q4 2025.

  • ORG Partners held 130 shares of Denali Therapeutics worth $2.15K as of Q4 2025.
  • Denali Therapeutics was a new ORG Partners position in Q4 2025.
  • Denali Therapeutics made up ﹤0.01% of ORG Partners's portfolio in Q4 2025, its #1434 holding.
  • 250 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2025.

Based on ORG Partners's 13F filing for Q4 2025, filed 14 Jan 2026.